Physician profile
Luis E Guerrero
NPI 1922015171
$10,942.45
in general payments reported to CMS, 2019-2025
31 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $539 · 2021: $2,040 · 2022: $1,742 · 2023: $1,625 · 2024: $1,558 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,238 · Education: $6.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,238.39 |
| Education | $6.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,515.40 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $2,131.18 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novo Nordisk INC | $1,459.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $596.24 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $489.17 | 2021-2025 | Repatha, Otezla, Otezla |
| Genzyme Corporation | $402.78 | 2021-2025 | |
| Lilly USA, LLC | $361.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Insmed, INC. | $342.04 | 2025 | Arikayce, Brinsupri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.12 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $312.36 | 2021-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $311.25 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $235.71 | 2019-2023 | |
| Amarin Pharma, INC. | $215.50 | 2019-2021 | |
| Electromed, INC. | $204.21 | 2019-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $154.10 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $131.30 | 2019-2020 | |
| Curonix LLC | $116.98 | 2022-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbott Laboratories | $103.70 | 2023-2025 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $78.31 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $74.50 | 2021-2025 | Eliquis |
| Pfizer INC. | $60.99 | 2022-2024 | |
| Hikma Pharmaceuticals USA | $57.49 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $47.09 | 2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $37.41 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $35.61 | 2019 | |
| Gilead Sciences, INC. | $35.11 | 2019 | |
| Daiichi Sankyo INC. | $32.72 | 2024 | Injectafer |
| United Therapeutics Corporation | $26.65 | 2025 | Tyvaso |
| Althera Pharmaceuticals LLC | $18.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.04 | 2021 | |
| Abbvie INC. | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Guerrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.